Hargett S, Wanebo H J, Pace R, Katz D, Sando J, Cantrell R
Am J Surg. 1985 Oct;150(4):456-60. doi: 10.1016/0002-9610(85)90153-9.
Interleukin-2, a lymphocyte-produced hormone or lymphokine, is required to support proliferation of antigen-triggered T lymphocytes and cytotoxic T cells that are considered essential elements for host tumor control. We have addressed the question of whether interleukin-2 production is altered in head and neck cancer patients, a group that is frequently immunosuppressed. Interleukin-2 production was measured by the tritium-labeled thymidine CT6 assay on the supernatants of peripheral blood lymphocytes of head and neck cancer patients and controls after 24 hour stimulation with phytohemagglutinin. The mean levels of interleukin-2 produced were 127 units (range 3 to 336 units) in the head and neck cancer patients versus 125 units (range 26 to 307 units) in the control group (not statistically significant). There were no significant differences in mean interleukin-2 values between cancer patients with stages I and II or III and IV disease compared with the control subjects. Twenty-seven percent of the cancer patients had interleukin-2 levels below the 10th percentile cutoff point (p = 0.015). The lymphocyte proliferative response to phytohemagglutinin was significantly depressed in the head and neck cancer patients compared with the control subjects. This did not correlate with interleukin-2 production abnormalities, except in patients with advanced disease, in whom there was a borderline correlation between phytohemagglutinin response and interleukin-2 production (correlation coefficient 0.23, p = 0.05). We conclude that the commonly observed depressed T-cell proliferative response to phytohemagglutinin in head and neck cancer patients is not explained by impaired interleukin-2 production.
白细胞介素 - 2是一种由淋巴细胞产生的激素或淋巴因子，它对于支持抗原触发的T淋巴细胞和细胞毒性T细胞的增殖是必需的，而这些细胞被认为是宿主肿瘤控制的关键要素。我们探讨了白细胞介素 - 2的产生在头颈癌患者中是否发生改变，这是一组经常出现免疫抑制的人群。通过在植物血凝素刺激24小时后，采用氚标记胸腺嘧啶核苷CT6测定法，对头颈癌患者和对照组外周血淋巴细胞的上清液进行检测，以测量白细胞介素 - 2的产生。头颈癌患者产生的白细胞介素 - 2平均水平为127单位（范围为3至336单位），而对照组为125单位（范围为26至307单位）（无统计学显著差异）。与对照组相比，I期和II期或III期和IV期疾病的癌症患者的白细胞介素 - 2平均水平无显著差异。27%的癌症患者白细胞介素 - 2水平低于第10百分位数的临界点（p = 0.015）。与对照组相比，头颈癌患者对植物血凝素的淋巴细胞增殖反应明显受到抑制。这与白细胞介素 - 2产生异常无关，除了晚期疾病患者，在这些患者中，植物血凝素反应与白细胞介素 - 2产生之间存在临界相关性（相关系数0.23，p = 0.05）。我们得出结论，头颈癌患者中常见的对植物血凝素的T细胞增殖反应受到抑制，并非由白细胞介素 - 2产生受损所解释。
